Description
Key facts
Detection method:Colorimetric,
Sample types:Citrate plasma, EDTA Plasma
Product details:
Plasma Kallikrein Assay Kit (ab241042) utilizes the ability of active Plasma Kallikrein to cleave a synthetic
NA-based peptide substrate to release pNA (OD405 nm), which can be easily quantified using a microplate reader. The Plasma Kallikrein Specific Inhibitor (PKSI) selectively inhibits the ability of Plasma Kallikrein to the cleave the synthetic substrate. The kit is easy-to-use and can detect PK activity of Purified Plasma Kallikrein and EDTA and citrated treated Plasma Samples.
Other Notes
This product was previously called K997 Biovision Plasma Kallikrein Activity Assay Kit (Colorimetric). Biovision was acquired by Abcam in 2021.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Plasma Kallikrein 1B also known as PKK or KLKB1 is a serine protease enzyme with an approximate mass of 88 kDa. It is important for the blood coagulation process. This protein is mainly expressed in the liver and circulates in the blood as the inactive precursor prekallikrein. Through cleavage prekallikrein converts into its active form plasma kallikrein. Plasma kallikrein exhibits various proteolytic activities influencing multiple substrates involved in hemostatic and inflammatory responses.
Biological function summary
Plasma Kallikrein 1B plays significant roles in the kinin-kallikrein system. Within this system it cleaves high-molecular-weight kininogen to release bradykinin a potent vasodilator. This enzyme is not part of a larger protein complex but operates independently to modulate various physiological responses. Plasma kallikrein's activity influences processes like pain vasodilation and inflammation making it important in homeostasis and acute-phase responses.
Pathways
Plasma Kallikrein 1B participates actively in the kallikrein-kinin and the contact activation pathways. In the kallikrein-kinin system it works alongside high-molecular-weight kininogen and factor XII which plays an important role in the intrinsic pathway of coagulation. Plasma kallikrein's enzymatic activities lead to the production of bradykinin and other peptides impacting blood pressure and inflammatory processes.
Plasma Kallikrein 1B associates strongly with hereditary angioedema and diabetic retinopathy. In hereditary angioedema its dysregulation leads to excessive bradykinin production causing episodes of swelling. In diabetic retinopathy elevated plasma kallikrein activity can exacerbate vascular complications. Plasma kallikrein's disorderly activities also connect it to other proteins like C1 inhibitor in these pathological conditions highlighting its importance in clinical studies.
